Search company, investor...

Founded Year



Series C | Dead

Total Raised


Last Raised


About Topica

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

Headquarters Location

1 Post Street Suite 875

San Francisco, California, 94104,

United States




Topica Patents

Topica has filed 1 patent.

The 3 most popular patent topics include:

  • internet television
  • teleconferencing
  • video codecs
patents chart

Application Date

Grant Date


Related Topics



Videotelephony, Teleconferencing, Video codecs, Web conferencing, Internet television


Application Date


Grant Date


Related Topics

Videotelephony, Teleconferencing, Video codecs, Web conferencing, Internet television



Latest Topica News

Data Vantage: Qashier, Endowus, Droom secure capital; Topica and others file financials

Aug 24, 2023

This web version of the DATA VANTAGE twice-weekly premium newsletter is available only to our premium subscribers. Unlock access by picking up any of our premium subscription plans .

Topica Frequently Asked Questions (FAQ)

  • When was Topica founded?

    Topica was founded in 1998.

  • Where is Topica's headquarters?

    Topica's headquarters is located at 1 Post Street, San Francisco.

  • What is Topica's latest funding round?

    Topica's latest funding round is Series C.

  • How much did Topica raise?

    Topica raised a total of $44.5M.

  • Who are the investors of Topica?

    Investors of Topica include Highland Capital Partners, August Capital, Moore Capital Management, Draper Richards, Morgan Stanley and 4 more.

  • Who are Topica's competitors?

    Competitors of Topica include OyaGen, Tobira Therapeutics, Anacor Pharmaceuticals, InterMune, Trius Therapeutics and 7 more.


Compare Topica to Competitors


OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology


PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

Azides Pharmaceuticals

Azides Pharmaceuticals, Inc is a developer of HIV drugs to treat viral strains resistant to existing medications such as azidothymidine, or AZT,

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.